A

Abbott

Makes heart devices, glucose sensors and lab tests

EPD Product Flows Expert

Full-TimeUpdated on 10/23/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Allschwil, Switzerland
In Person
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A bachelor's or master's degree in Supply Chain Management, Logistics, Operations Management, Business Administration, or a related field.
  • Five to ten years of experience in pharmaceutical supply chain, distribution, transportation, and logistics operations.
  • Experience in customs and trade compliance within a regulated pharmaceutical environment.
  • Strong understanding of pharmaceutical supply chain processes, business operations, and end-to-end supply chain functions.
  • Proven project management experience leading complex cross-functional initiatives.
  • Experience with ERP and supply chain systems, including SAP ECC, SAP APO, TrackWise, Planisware, and DARIUS.
  • Advanced proficiency in Microsoft Office applications, including Excel, Visio, and Power BI.
  • Strong project management, organizational, analytical, and problem-solving skills, with the ability to manage multiple priorities and drive effective decision-making.
  • Excellent stakeholder management, communication, influencing, and negotiation skills, with the ability to collaborate across functions, regions, and organizational levels in a matrix environment.
  • Proven ability to lead change, drive continuous improvement, and successfully deliver complex initiatives in dynamic business environments.
  • Deep knowledge of supply chain operations, distribution, transportation, customs and compliance, and third-party logistics.
  • Ability to coach, develop, and inspire teams while fostering collaboration and operational excellence.
  • Strategic mindset with the ability to anticipate risks, adapt to changing business needs, and deliver high-quality results.
  • Fluent English, written and spoken.
  • Strong ownership and accountability; detail-oriented and committed to quality, accuracy, and continuous improvement; resilient, adaptable, and effective under pressure and ambiguity; collaborative with strong judgment, interpersonal, and conflict-resolution skills; and strong intercultural competence for global environments.
Responsibilities
  • Govern the global product-flow framework, ensuring financial, tax, customs, trade compliance, and supply chain requirements are reflected in efficient and compliant physical and financial product flows.
  • Serve as the subject matter expert for product-flow design and supply chain network considerations, supporting strategic sourcing decisions, new product introductions, biosimilars, samples, and commercial portfolio expansion.
  • Coordinate evaluation, approval, documentation, and communication of new product flows and changes across global, regional, and local stakeholders.
  • Maintain and improve product-flow governance, databases, tools, and processes to ensure accurate documentation, financial compliance, and transparency across the supply chain network.
  • Lead and execute cross-functional supply chain projects related to product-flow optimization, network changes, warehouse and distribution setup, compliance requirements, process improvements, and operational efficiencies.
  • Provide guidance, training, and expert support to Supply Chain Operations and other functions on product-flow models, operational processes, and implementation requirements.
  • Develop and maintain product-flow governance documentation, processes, and communication materials.
  • Maintain the global EPD Product Flow Database and related master data, ensuring accuracy, completeness, and compliance.
  • Manage the end-to-end approval process for new product flows and modifications to existing flows.
  • Ensure compliance with company policies and external requirements related to transfer pricing, tax, VAT, customs, trade compliance, and legal entity structures.
  • Serve as the primary point of contact for product-flow-related inquiries across the organization.
  • Support sourcing decisions, supply chain network optimization initiatives, and portfolio expansion projects.
  • Maintain landed-cost analyses and scenario evaluations to support business decision-making.
  • Assess operational, financial, compliance, and service implications of alternative supply chain network configurations.
  • Organize, facilitate, and lead Product Flow Council meetings.
  • Review, assess, and present proposed product flows and supply chain network changes.
  • Drive stakeholder alignment across Supply Chain, Finance, Tax, Customs and Trade, Quality, Regulatory, Legal, Commercial, and Operations functions.
  • Monitor execution of approved actions and ensure timely implementation of decisions from a Supply Chain Operations perspective, including master data setup, pricing, plant extensions, transportation lanes, and related operational requirements.
  • Lead Supply Chain Operations projects and workstreams related to product-flow changes, network optimization, warehouse transitions, relabeling activities, product launches, biosimilars, and operational improvements.
  • Drive operational implementation of approved product-flow and network changes, ensuring operational readiness, compliance, business continuity, and seamless execution.
  • Define and manage implementation plans, timelines, deliverables, risks, and stakeholder alignment for Supply Chain Operations activities.
  • Coordinate cross-functional teams and execute key operational deliverables related to master data, transportation, customer service, warehousing, systems, and distribution.
  • Track project progress, milestones, risks, dependencies, and timelines, ensuring appropriate governance and timely execution of Supply Chain Operations activities.
  • Provide regular status updates, risk assessments, and recommendations to senior leadership, project sponsors, and key stakeholders.
  • Drive continuous improvement initiatives to enhance operational efficiency, service performance, compliance, and cost optimization.
  • Provide guidance on sample-related logistics, inventory movement, and compliance requirements; determine sample product flows.
  • Coordinate biosimilar samples, including TMT, registration/submission, and commercial samples, with the TPM on sample availability, documentation, and service purchase-order requests.
  • Act as the Supply Chain Product Flow lead for new product introduction projects, including biosimilars and portfolio acquisitions.
  • Coordinate product-flow setup and supply chain execution requirements for product launches, onboarding activities, and implementation projects.
  • Ensure readiness of operational supply chain elements, including product flows, transportation validation, transportation lanes, warehouse setup, systems, and related master data.
  • Partner with cross-functional stakeholders to ensure successful launch execution and uninterrupted product supply.
Desired Qualifications
  • Additional language skills, such as French, German, or Spanish, are an advantage.

About the company

A

Abbott

View
Website

Abbott makes medical devices, diagnostic tests, nutrition products and branded generic drugs for hospitals, laboratories, pharmacies and patients. Its best-known product is the FreeStyle Libre, a coin-sized sensor worn on the upper arm that tracks blood sugar around the clock without routine finger pricks. Its other lines run from heart valves, pacemakers and brain stimulators to lab analyzers, rapid tests and mail-in colon cancer screening kits, and Abbott earns money by selling these products to health systems, labs, retailers and consumers. The company was founded in 1888 by Chicago physician Wallace Abbott and is based in Abbott Park, Illinois.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to Abbott

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Devices carry the growth: Abbott's device sales rose 8.4% on a comparable basis from April to June 2026.
  • Diabetes teams get a launch to build: FDA authorized Libre Duo, the first glucose and ketone sensor, in August 2026.
  • Abbott bought a cancer screening business: its roughly $21 billion Exact Sciences purchase closed in March 2026.

What critics are saying

  • Formula lawsuits linger: after a $670 million August 2026 settlement, about 1,700 suits over preemie formula remain.
  • Nutrition staff sit in a shrinking unit: Abbott's nutrition sales fell 3.6% comparably from April to June 2026.
  • Abbott's top product drew a severe recall: FDA flagged Libre 3 sensor errors linked to seven deaths in January 2026.

What makes Abbott unique

  • Abbott's drug arm skips the US: it sells branded generic medicines only in markets such as India and Latin America.
  • Abbott sells to grocery shoppers too: Similac formula and Ensure shakes sit on store shelves, unlike device rivals.
  • Abbott's heart implant reports to patients: CardioMEMS lets heart failure patients read their own artery pressure on phones.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Professional Development Budget
  • Wellness Program

Growth & Insights and Company News

6 month growth

-6%

1 year growth

5%

2 year growth

5%
PR Newswire
Oct 23rd, 2026
Abbott's whole-genome Oncodetect test boosts colorectal cancer recurrence detection sensitivity by 30%

Abbott said its whole-genome sequencing Oncodetect test detected colorectal cancer recurrence far more often than the whole-exome version. New Beta-CORRECT data presented at the European Society for Medical Oncology Congress showed a 30-percent absolute improvement in sensitivity within two years of surgery, using a single post-surgery blood draw. The test reached 72.2% sensitivity, against 42.2% for the earlier test. Among 157 patients tested with both, it found circulating tumour DNA (ctDNA) in all 29 patients the older test caught, plus 15 more. Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence. Two-year disease-free survival was 36.2%, versus 92.3% for ctDNA-negative patients. The study analysed samples from 279 patients, mostly with stage II and III disease. The test tracks up to 5,000 DNA variants unique to each tumour.

Telangana Today
Oct 22nd, 2026
FSSAI notices put baby food and nutrition product claims under scrutiny.

FSSAI notices put baby food and nutrition product claims under scrutiny. FSSAI has issued show-cause notices to major food and nutrition companies over claims made for infant formula and children's nutritional drinks. The regulator has sought scientific evidence and explanations, while also questioning the promotion of infant formula products on social media. Published Date - 22 October 2026, 06:10 PM Hyderabad: Wrapping commercial products in scientific-sounding jargon, emotionally playing on parental anxieties to coax them into buying baby food, and pushing unverified health claims to boost sales of health and baby products has, for a long time, been a standard playbook for companies. However, such deceptive and misleading claims are finally being met with resistance, as food regulators and apex courts have started insisting that before flooding the markets with their untested products, MNCs and nutritional giants must prove what they claim in the laboratory first. The recent wave of show-cause notices to Nestle, Abbott, Mead Johnson Nutrition and Zydus, by the Food Safety and Standards Authority of India (FSSAI), against such deceptive advertisements, unverified health claims and promotional violations, has put a spotlight back on the practice of misleading vulnerable consumers and making profit at their cost. The FSSAI action has come in the wake of the Supreme Court's scathing remarks over deceptive advertising and public health safety. The apex court slammed companies that make misleading claims and even hauled up regulators for dragging their feet on clear front-of-pack warning labels, questioning whether undue pressure from powerful food manufacturers has allowed public health interests to be sidelined. The food regulator notices have also made it clear that companies can no longer treat clinical trials as marketing tools. From now on, any claim of enhanced growth due to a product or claims that a specific additive will make a baby's brain grow smarter or better will have to undergo rigorous peer-reviewed scientific scrutiny evaluated directly by regulatory authorities. The authorities have also included social media influencers and digital content creators in regulatory warnings to address a major loophole. In the last few years, such influencers and content creators, through promotional reels and unboxing videos, casually recommend specific baby milk substitutes under the guise of lifestyle advice. Such claims made by influencers are now firmly in the crosshairs of regulatory agencies. Public health specialists familiar with the issue said that FSSAI warnings to big brands over fake health claims on drinks, baby formula, and social media advertisements show that much of the industry relies on guesswork and claims, not on hard facts. Infant Nutrition - Companies rely on scientific jargon, unverified health claims, and parental anxieties to boost sales - Food regulators and the Supreme Court are demanding that nutritional giants prove their claims in the lab before launching products - FSSAI has issued show-cause notices to Nestle, Abbott, Mead Johnson Nutrition, and Zydus over deceptive ads and promotional violations - Companies can no longer use clinical trials as marketing tools - Physical growth and brain-development claims must face rigorous peer-reviewed scrutiny - Regulatory warnings to influencers and content creators who casually push baby milk substitutes under the guise of lifestyle advice - Crackdown exposes an industry built on guesswork and unverified claims rather than hard data * Follow Us: Discover more Try New Foods

Yahoo Finance
Oct 21st, 2026
Abbott to spin off $8.5B nutrition business, with Similac and Pedialyte, by end of 2027

Abbott Laboratories plans to spin off its nutrition business into an independent company with about $8.5 billion in annual sales. Shares fell 3.9% to $98.44 in premarket trading. Daniel Salvadori, an executive vice president, will lead the new company, which will house the Pedialyte and Similac brands. Abbott shareholders would own shares in both companies. Abbott expects to complete the separation by the end of 2027. Afterwards, it would have sales of about $42 billion, focused on medical devices, diagnostics, and established medicines. The company has faced years of litigation over a baby-formula facility, including a $385 million settlement in September and a $670 million settlement in August.

MarketScreener
Oct 21st, 2026
Abbott posts lower 3Q profit, despite higher sales.

Abbott posts lower 3Q profit, despite higher sales. Published on 10/21/2026 at 08:33 am EDT By Connor Hart Abbott reported higher sales in the latest quarter, though profit fell as operating costs and expenses increased. The healthcare company on Wednesday posted a third-quarter profit of $920 million, or 53 cents a share, down from $1.64 billion, or 94 cents a share, a year earlier. Stripping out certain one-time items, earnings came in at $1.42 a share, in line with the expectations of analysts polled by FactSet. Net sales climbed more than 14%, to $13.01 billion, just topping Wall Street models for $12.99 billion. Sales across Abbott's nutrition business rose 5.1% to $2.26 billion. The company separately on Wednesday announced plans to carve out its nutrition unit into an independent company, housing brands such as Pedialyte electrolyte beverages and Similac infant formula. Diagnostics sales jumped 47% to $3.31 billion. Sales across the company's established-pharmaceuticals and medical-device businesses were up 6.8% and 6.9%, respectively. Total operating costs and expenses rose 25% to $11.66 billion, in part reflecting higher input costs as well as research-and-development spending. Chief Executive Robert Ford said the quarterly results reflect balanced growth across the company's portfolio. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead," he added. For the year, Abbott expects adjusted earnings to come in between $5.50 and $5.55 a share on comparable sales growth of about 6%. The company had previously guided for adjusted earnings of $5.45 to $5.60 a share on comparable sales growth of 6.5% to 7.5%. The company additionally guided for adjusted earnings of $1.62 to $1.67 a share in the current quarter, compared with analyst views for $1.64 a share. Write to Connor Hart at [email protected] (END) Dow Jones Newswires 10-21-26 0831ET (C) Dow Jones - 2026

ABC Money
Oct 21st, 2026
Abbott confirms $8.5bn Nutrition spin-off, cuts sales outlook.

Abbott confirms $8.5bn Nutrition spin-off, cuts sales outlook. Abbott Laboratories (NYSE: ABT) said on 21 October 2026 that it intends to separate its global Nutrition business into an independent, publicly traded company, carving out a unit with roughly $8.5bn in annual sales built around household names including Similac, Ensure, Pedialyte, PediaSure and Glucerna. The Abbott Nutrition spin-off is structured as a tax-free distribution of shares to existing Abbott shareholders, with completion targeted by the end of 2027. Daniel Salvadori, currently Abbott's executive vice president and group president for Established Pharmaceuticals and Nutritional Products, has been named chief executive of the new company, according to StreetInsider, which also reports the unit employs around 16,000 people across 14 manufacturing sites. The remaining Abbott, stripped of Nutrition, is projected to carry about $42bn in annual sales and roughly 106,000 employees, per Securities.io. A business that has been losing momentum. The pitch to shareholders is straightforward: freed of a slower-growing consumer unit, Abbott expects "accelerated sales growth and an expanded margin profile" on the diagnostics, devices and pharmaceuticals that remain. That framing sits awkwardly next to the Nutrition division's recent trading. Worldwide Nutrition sales came in at $2,144m in the second quarter of 2026, down 3.1% year-on-year, following an 8.9% reported decline in the fourth quarter of 2025 that prompted pricing actions, according to an exhibit filed with the SEC. Spinning off a business that has been shrinking is not unusual - it often lets the parent's growth rate look better by subtraction - but it does mean the new standalone company starts life with a sales trend to reverse rather than extend. The separation is not yet a done deal. It remains subject to regulatory approvals, the effectiveness of a Form 10 registration statement with the SEC, and final sign-off from Abbott's board, StreetInsider notes - the standard sequence for a US spin-off, but one that leaves roughly fourteen months of execution risk before shareholders actually hold stock in the new entity. Why the market shrugged, then sold. Investors did not treat the day as an unambiguous win. Abbott shares slid in premarket trading and kept falling into the session, dropping roughly 1.4% to 2% according to Investing.com, with the stock closing the day down 3.37% at $98.55. The reason wasn't the spin-off mechanics themselves but what accompanied them: Abbott simultaneously trimmed its full-year 2026 comparable sales-growth guidance to around 6%, down from a prior range of 6.5% to 7.5%, citing weakness in its medical device business, as Reuters reported. That guidance cut landed on the same morning as the third-quarter results underpinning it. Abbott's own release showed revenue of $13.01bn, up 14.5% on a reported basis and 7.0% on a comparable basis, with adjusted diluted earnings per share of $1.42 - in line with estimates - while the company held its full-year adjusted EPS guidance at $5.50 to $5.55. Investors, in other words, got a corporate restructuring story and a soft core-growth story in the same press cycle, and chose to price the latter. Precedent, and the cost of standing alone. This would be Abbott's second major separation in roughly a decade and a half. The company spun off AbbVie, its research-based pharmaceuticals arm, in January 2013, a transaction detailed in its fiscal 2012 annual report. That split ultimately let both businesses pursue distinct strategies - AbbVie as a branded-drug specialist, Abbott as a diversified health-products company - and investors will be watching whether the Nutrition carve-out follows a similar arc or struggles with the slower growth the segment has shown lately. The timing carries one more complication for a newly independent company likely to take on its own debt load: the 10-year US Treasury yield stood at 5.15% on 19 October 2026, up from 5.09%, according to Federal Reserve data. A standalone Nutrition company raising capital or refinancing in that environment faces materially higher financing costs than it would have a few years ago, a detail that rarely makes the press release but tends to show up in the first set of standalone accounts. Abbott's spin-off also joins a crowded run of 2026 portfolio break-ups, including National Fuel Gas's planned separation of its upstream and gathering business and Corteva's completed spin-off of its seed unit into Vylor Inc. For Abbott shareholders, the practical markers to watch are the Form 10 filing that will set out the new company's standalone financials, and whether the next quarterly print shows Nutrition's sales decline stabilising before the 2027 distribution date arrives. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.